Rapport Therapeutics (RAPP) Depreciation & Amortization (CF) (2023 - 2026)
Rapport Therapeutics (RAPP) reported Depreciation & Amortization (CF) of $227000.0 for Q1 2026, down 6.97% year-over-year from $244000.0 in Q1 2025, and down 14.34% quarter-over-quarter from $265000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $227000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $227000.0, down 6.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (up 7.41% YoY), and the FY2025 annual result was $1.0 million, up 21.22% from the prior year.
- Depreciation & Amortization (CF) slipped to $227000.0 in Q1 2026 per RAPP's latest filing, from $265000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $265000.0 in Q4 2025 and troughed at $23000.0 in Q3 2023.
- A 4-year average of $188250.0 and a median of $223000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) jumped 852.17% in 2024, then retreated 6.97% in 2026.
- A 4-year view of Depreciation & Amortization (CF) shows it stood at $53000.0 in 2023, then soared by 390.57% to $260000.0 in 2024, then gained by 1.92% to $265000.0 in 2025, then fell by 14.34% to $227000.0 in 2026.
- Business Quant data shows RAPP's Depreciation & Amortization (CF) at $227000.0 in Q1 2026, $265000.0 in Q4 2025, and $256000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | 227,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 265,000.00 |
| Dec 31, 2025 | 265,000.00 |
| Sep 30, 2025 | 256,000.00 |
| Sep 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 252,000.00 |
| Jun 30, 2025 | 252,000.00 |
| Mar 31, 2025 | 244,000.00 |
| Mar 31, 2025 | 244,000.00 |
| Dec 31, 2024 | 260,000.00 |
| Dec 31, 2024 | 260,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Jun 30, 2024 | 208,000.00 |
| Jun 30, 2024 | 208,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Dec 31, 2023 | 53,000.00 |